Top Tweets for #iberdd

1 day ago

@SagarLonialMD @US_FDA @Amyloid_Planet @DrOlaLandgren 57) Our take: #IberDd is positioned as a new standard-of-care option for #RRMM that can be used as early as 1st relapse, across diverse clinical settings including community practice. The maturing #PFS data will be the next thing to watch closely. #IMS2026 #RRMM

1

0

0

0

232

1 day ago

@SagarLonialMD @US_FDA @Amyloid_Planet @DrOlaLandgren 56) @SagarLonialMD: These data suggest that #IberDd has a higher chance of inducing MRD negative CR but is subject to cross trial comparisons and other differences in patient populations and perhaps a time bias.

1

0

0

0

362

1 day ago

@SagarLonialMD @US_FDA @Amyloid_Planet 54) A companion matching-adjusted indirect comparison of #IberDd vs Dd- and #IMiD-containing regimens was also presented here at #IMS2026 by @DrOlaLandgren:

onc_ce's tweet photo. @SagarLonialMD @US_FDA @Amyloid_Planet 54) A companion matching-adjusted indirect comparison of #IberDd vs Dd- and #IMiD-containing regimens was also presented here at #IMS2026 by @DrOlaLandgren: https://t.co/qd37XeLeXr

1

0

0

0

388

1 day ago

@SagarLonialMD @US_FDA 48) Why it matters for access: because there is no #CRS, no #ICANS, & no step-up dosing, #IberDd is deliverable in community practice. Depth of response of this magnitude, without specialized infrastructure, is exactly the gap we described at the top of this 🧵. #RRMM

1

0

0

0

873

1 day ago

@SagarLonialMD @US_FDA 45) Bottom line from Lonial et al at #IMS2026: #IberDd significantly improved MRD-negative #CR vs #DVd (41.1% vs 20.7%; P<0.0001; OR 2.75), consistently across subgroups including #LEN-exposed & LEN-refractory pts. Evaluation of the dual #PFS endpoint is ongoing.

1

0

0

0

503

1 day ago

@SagarLonialMD @US_FDA 44) Deaths were reported in 11.1% (#IberDd) vs 15.5% (#DVd), primarily from progressive disease. Grade 5 TEAEs: 5.4% vs 2.5%, of which 1.5% vs 1.0% were considered treatment-related. #EXCALIBER_RRMM

1

0

0

0

120

1 day ago

@SagarLonialMD @US_FDA 43) Also worth noting: any-grade #hypogammaglobulinemia 16.7% (#IberDd) vs 10.3% (#DVd), with #IGRT given to 27.9% vs 13.7%. #VTE occurred in 5.9% vs 3.9%. There were no grade 3/4 events with IberDd, with mandatory thromboprophylaxis in that arm. #RRMM

1

0

0

0

212

1 day ago

@SagarLonialMD @US_FDA 42) Infections: any infection 78.9% (#IberDd) vs 69.6% (#DVd); grade 3 35.8% vs 21.1%, grade 4 3.4% vs 0.5%. Pneumonia 23.5% vs 11.3%. Only 1.5% (n=3) discontinued iber due to infection; fatal infections were low & similar (2.0% vs 1.5%). #EXCALIBER_RRMM

onc_ce's tweet photo. @SagarLonialMD @US_FDA 42) Infections: any infection 78.9% (#IberDd) vs 69.6% (#DVd); grade 3 35.8% vs 21.1%, grade 4 3.4% vs 0.5%. Pneumonia 23.5% vs 11.3%. Only 1.5% (n=3) discontinued iber due to infection; fatal infections were low & similar (2.0% vs 1.5%). #EXCALIBER_RRMM https://t.co/pPObCzN3uH

1

0

0

0

365

1 day ago

@SagarLonialMD @US_FDA 41) Contrast the two arms’ toxicity signatures: thrombocytopenia was LOWER with #IberDd (36.8% any grade; 12.7% grade 3/4) than #DVd (62.7%; 44.1%). Rates of grade 3/4 diarrhea, fatigue, & rash were low & similar between arms. #RRMM

1

0

0

0

568

1 day ago

@SagarLonialMD @US_FDA 40) How was neutropenia managed? 82.4% of #IberDd pts received #G_CSF. Iber dose modifications for neutropenia: 51.5% dose interruption, 13.2% dose reduction, & only 1.0% (n=2) discontinuation. Grade 3/4 rates fell sharply after cycles 1–2. #IMS2026

onc_ce's tweet photo. @SagarLonialMD @US_FDA 40) How was neutropenia managed? 82.4% of #IberDd pts received #G_CSF. Iber dose modifications for neutropenia: 51.5% dose interruption, 13.2% dose reduction, & only 1.0% (n=2) discontinuation. Grade 3/4 rates fell sharply after cycles 1–2. #IMS2026 https://t.co/hu52EgPE4k

1

0

0

0

791

1 day ago

@SagarLonialMD @US_FDA 39) The dominant toxicity is on-target & reversible: #neutropenia in 89.2% any grade / 84.3% grade 3/4 with #IberDd vs 24.0%/11.3% with #DVd. Febrile neutropenia, importantly, was uncommon at 5.4%. #RRMM

1

0

0

0

516

1 day ago

@SagarLonialMD @US_FDA 38) Safety: the profile was generally predictable & manageable, consistent with the known effects of #CELMoDs & Dd. Any-grade #TEAEs occurred in essentially all pts in both arms; grade 3/4 in 91.7% (#IberDd) vs 70.1% (#DVd). #EXCALIBER_RRMM

1

0

0

0

464

1 day ago

@SagarLonialMD @US_FDA 37) For cross-trial context (with all the usual caveats about design, MRD methodology, population, & follow-up differing) the 41% MRD-negative CR rate w/#IberDd sits at the upper end of reported #RRMM triplet data (DPd 9%, DKd 14%, IsaKd 20%, BPd 24%, BVd 25%). #RRMM

onc_ce's tweet photo. @SagarLonialMD @US_FDA 37) For cross-trial context (with all the usual caveats about design, MRD methodology, population, & follow-up differing) the 41% MRD-negative CR rate w/#IberDd sits at the upper end of reported #RRMM triplet data (DPd 9%, DKd 14%, IsaKd 20%, BPd 24%, BVd 25%). #RRMM https://t.co/lgph5k60uq

1

0

0

0

377

1 day ago

@SagarLonialMD @US_FDA 36) Depth of response overall: #ORR 88.9% with #IberDd vs 76.1% with #DVd. ≥ #VGPR 74.4% vs 61.5%. And ≥ CR 45.9% vs 24.9%; IberDd nearly DOUBLED the ≥ CR rate. (Not adjusted for multiplicity; not formally tested.) #EXCALIBER_RRMM

onc_ce's tweet photo. @SagarLonialMD @US_FDA 36) Depth of response overall: #ORR 88.9% with #IberDd vs 76.1% with #DVd. ≥ #VGPR 74.4% vs 61.5%. And ≥ CR 45.9% vs 24.9%; IberDd nearly DOUBLED the ≥ CR rate. (Not adjusted for multiplicity; not formally tested.) #EXCALIBER_RRMM https://t.co/SGklndBImd

1

0

0

0

122

1 day ago

@SagarLonialMD @US_FDA 33) Put differently: #IberDd doubled the rate of MRD-negative CR versus an active anti-#CD38 triplet, in an early-relapse population, with a fully outpatient, non-#CRS regimen. #RRMM #myeloma

onc_ce's tweet photo. @SagarLonialMD @US_FDA 33) Put differently: #IberDd doubled the rate of MRD-negative CR versus an active anti-#CD38 triplet, in an early-relapse population, with a fully outpatient, non-#CRS regimen. #RRMM #myeloma https://t.co/7HoDsQZYe8

1

23

0

0

877

1 day ago

@SagarLonialMD @US_FDA 32) THE HEADLINE: MRD-negative #CR at any time was 41.1% with #IberDd vs 20.7% with #DVd. This is a proportion difference of 20.1% (95% CI 11.5–28.6; P<0.0001), odds ratio 2.75 (95% CI 1.77–4.30). The dual primary MRD endpoint was met. #EXCALIBER_RRMM #IMS2026

1

23

0

0

960

1 day ago

@SagarLonialMD @US_FDA 31) Disposition at median follow-up 15.7 months: 62.3% of #IberDd pts remained on treatment vs 46.0% on #DVd. Discontinuation for progressive disease: 15.9% vs 35.2%. Iber relative dose intensity was high at 90.5%; discontinuations for AEs were infrequent. #IMS2026

onc_ce's tweet photo. @SagarLonialMD @US_FDA 31) Disposition at median follow-up 15.7 months: 62.3% of #IberDd pts remained on treatment vs 46.0% on #DVd. Discontinuation for progressive disease: 15.9% vs 35.2%. Iber relative dose intensity was high at 90.5%; discontinuations for AEs were infrequent. #IMS2026 https://t.co/1JbceDWppK

1

0

0

0

545

1 day ago

@SagarLonialMD @US_FDA 29) Who enrolled? #IberDd n=207, #DVd n=213. Median age 68 (range 37–85); 18.8% were ≥ 75 years. High-risk cytogenetics in 23.2%; expanded high-risk (adding amp1q21) in ~50%. Soft-tissue plasmacytomas in ~11%. Arms were well balanced. #EXCALIBER_RRMM

1

0

0

0

675

1 day ago

@SagarLonialMD @US_FDA 26) Endpoint architecture: MRD-negative #CR was assessed in the first 420 pts randomized to 1.0-mg #IberDd or #DVd with ≥ 12 months’ follow-up or early discontinuation; #PFS is being assessed in all 800 pts. #IMS2026 #RRMM

1

0

0

0

30

1 day ago

@SagarLonialMD @US_FDA 24) Dosing, #IberDd arm: Iber 1.0 mg orally once daily on D1–21 of each 28-day cycle; #DARA 1800 mg SC on D1/8/15/22 in C1–2, D1/15 in C3–6, then D1 from C7; #DEX 40 mg (or 20 mg if ≥ 75 y, BMI < 18.5, or steroid intolerance). All-oral CELMoD + SC mAb. #RRMM

1

0

0

0

699

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users